|View printer-friendly version|
|July 20, 2016 4:03 p.m.|
|Teva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics|
The notes will be sold at a price of 99.644%, 99.231% and 98.898% of the
principal amount thereof, respectively, and will be guaranteed by
“The success of our European bond offering capitalized on the strong
demand for our
The net proceeds from this Eurobond offering will be approximately €3.96
billion, after underwriting discounts and estimated offering expenses.
Teva intends to use the net proceeds from this offering (and the USD and
contemplated CHF offerings) towards the cash portion of the purchase
price for its previously announced acquisition of
The offering is being made outside
This communication is not an offer for sale of any securities of
In member states of the European Economic Area, the securities are being offered only to qualified investors within the meaning of Directive 2011/71/EC, as amended, in accordance with the respective regulations of each member state in which the securities are being offered.
This communication is only being distributed to and is only directed at
(i) persons who are outside the
This document is an advertisement for purposes of applicable measures implementing Directive 2003/71/EC and amendments thereto (the “Prospectus Directive”) and is not a prospectus for the purposes of the Prospectus Directive.
In connection with the issue of the notes, one or more of the managers (or persons acting on behalf of any of the managers) may over-allot notes or effect transactions with a view to supporting the market prices of the notes at a level higher than that which might otherwise prevail. However, there is no assurance that such managers (or persons acting on behalf of any such manager) will undertake stabilization action. Such stabilizing, if commenced, may be discontinued at any time and, if begun, must be brought to an end after a limited period. Any stabilization action or overallotment must be conducted by the relevant manager (or persons acting on behalf of such manager) in accordance with all applicable laws and rules.
Teva’s Safe Harbor Statement under the
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone®
(which faces competition from orally-administered alternatives and a
generic version); our ability to consummate the acquisition of
Teva Pharmaceutical Industries Ltd.